APA (7th ed.) Citation

A, N., L, N., I, F., E, C., & V, D. B. (2017). Impact of empagliflozin on subclinical left ventricular dysfunctions and on the mechanisms involved in myocardial disease progression in type 2 diabetes: Rationale and design of the EMPA-HEART trial. Cardiovascular diabetology, 16(1), 130. https://doi.org/10.1186/s12933-017-0615-6

Chicago Style (17th ed.) Citation

A, Natali, Nesti L, Fabiani I, Calogero E, and Di Bello V. "Impact of Empagliflozin on Subclinical Left Ventricular Dysfunctions and on the Mechanisms Involved in Myocardial Disease Progression in Type 2 Diabetes: Rationale and Design of the EMPA-HEART Trial." Cardiovascular Diabetology 16, no. 1 (2017): 130. https://doi.org/10.1186/s12933-017-0615-6.

MLA (9th ed.) Citation

A, Natali, et al. "Impact of Empagliflozin on Subclinical Left Ventricular Dysfunctions and on the Mechanisms Involved in Myocardial Disease Progression in Type 2 Diabetes: Rationale and Design of the EMPA-HEART Trial." Cardiovascular Diabetology, vol. 16, no. 1, 2017, p. 130, https://doi.org/10.1186/s12933-017-0615-6.